What is Signify Bio?
Signify Bio is a private biotechnology company headquartered in Dallas, Texas, founded in 2025. The company is dedicated to pioneering in situ protein therapeutics, utilizing the body's inherent protein production capabilities. Its innovative approach is powered by proprietary platforms, including SEND (Signal peptide Engineered Nucleic acid Design) and iPhos lipid nanoparticles, which facilitate precise, localized delivery of therapeutic proteins. In collaboration with the University of Texas Southwestern Medical Center, Signify Bio aims to develop personalized medicines for a range of chronic and genetic disorders through cutting-edge nucleic acid and protein engineering.
How much funding has Signify Bio raised?
Signify Bio has raised a total of $15M across 1 funding round:
Other Financing Round
$15M
Other Financing Round (2025): $15M with participation from Actium Group, Danaher, BrightEdge, and Eli Lilly
Key Investors in Signify Bio
Actium Group
Actium Group is a management consulting firm specializing in business growth and process optimization for small and medium-sized businesses, suggesting a strategic interest in operational scaling and efficiency.
Danaher
Danaher Corporation is a diversified conglomerate with significant operations in biotechnology, life sciences, and diagnostics, providing integrated solutions for therapeutic product development and manufacturing, indicating a strong alignment with Signify Bio's technological focus.
BrightEdge
ACS BrightEdge, the investment arm of the American Cancer Society, focuses on catalyzing scientific, social, and sustainable impact in cancer care, suggesting an interest in innovative oncology and therapeutic solutions.
What's next for Signify Bio?
With a substantial enterprise-level funding round and a major strategic investment, Signify Bio is poised for accelerated development and commercialization of its novel therapeutic platforms. The company's focus on in situ protein therapeutics and personalized medicine, supported by advanced technologies like SEND and iPhos, positions it to address significant unmet needs in chronic and genetic disorders. This latest financing is expected to fuel further research and development, expand its collaborative efforts, and potentially scale its manufacturing capabilities to bring its innovative treatments to patients.
See full Signify Bio company page
